For research use only. Not for therapeutic Use.
LP-184 (compound 6), an acylfulvene analog, inhibits tumor growth. LP-184 has potent anti-cancer activity in the ovarian, colon, prostate and pancreatic cell lines. (patent WO2007019308A2).
LP-184 inhibits the growth of HT29, OVCAR-3, AsPC-1 and PC-3, with GI50s of 0.68, 0.6, 16 and 0.14 μM, respectively[1].
LP-184 displays IC50s of 800nM and 210 nM for anti-cancer activitie in the thymidine incorporation into cellular DNA (2 hour) and Trypan blue (48 hour) assay[1].
LP-184 (7.5 and 10 mg/kg; i.p.; 21 day) has potent 15 anti-tumor activity against MV522 tumors, producing 4/6 and 5/5 partial responses, respectively[1].
| Catalog Number | I044397 |
| CAS Number | 924835-67-6 |
| Synonyms | 1-hydroxy-1-[[(5’R)-5′-hydroxy-2′,5′,7′-trimethyl-4′-oxospiro[cyclopropane-1,6′-indene]-1′-yl]methyl]urea |
| Molecular Formula | C16H20N2O4 |
| Purity | ≥95% |
| InChI | InChI=1S/C16H20N2O4/c1-8-6-10-12(11(8)7-18(22)14(17)20)9(2)16(4-5-16)15(3,21)13(10)19/h6,21-22H,4-5,7H2,1-3H3,(H2,17,20)/t15-/m0/s1 |
| InChIKey | VWMPVAZEBAKLFR-HNNXBMFYSA-N |
| SMILES | CC1=C(C2=C(C3(CC3)C(C(=O)C2=C1)(C)O)C)CN(C(=O)N)O |
| Reference | [1]. Trevor C. Mcmorris, et al. Illudin analogs useful as anticancer agents. WO2007019308A2. |
